Cancer Treatment Breakthroughs: Saving Lives but Funding Remains Elusive
The case of six-year-old Lianna Munir, who was diagnosed with a rare form of leukemia two years ago, is a stark reminder of the progress being made in pediatric cancer treatment. Thanks to cutting-edge therapies like CAR T-cell therapy, Munir's leukemia has become undetectable, and she's now back to living a relatively normal life.
Munir's experience is just one example of how advancements in pediatric cancer treatments are revolutionizing childhood cancer care. The American Association for Cancer Research (AACR) recently released a report highlighting the successes and challenges in this field. According to the report, funding for pediatric cancer research has historically been significantly lower than that for adult cancer research.
In 2021, only about 4% of federal cancer research dollars were allocated to childhood cancer. This is concerning given the significant strides being made in developing new treatments. In the past decade, over 20 molecularly-targeted therapies and more than 10 immunotherapies have been approved for pediatric cancers, including CAR T-cell therapy.
These advancements have enabled clinicians to tailor treatment plans for specific types of pediatric cancers based on their molecular profiles. Gene editing, liquid biopsy, and artificial intelligence are also being explored as new therapeutic options.
However, despite these gains, there is still much work to be done. Pediatric brain cancers remain a leading cause of death among children, with five-year survival rates ranging from below 25% for some types. Chronic health conditions affecting children who have survived cancer are also a pressing concern, with up to 90% of survivors experiencing at least one long-term condition by adulthood.
The AACR report emphasizes the need for increased funding to continue advancing pediatric cancer research. The organization is advocating for more resources from the National Institutes of Health and other sources to develop new treatments and improve existing ones.
As Munir's mother, Adrian Horn, so eloquently put it, "If we hit a plateau, we don't have a next step to go to. We need to keep being ready for it when it doesn't work anymore." The hope is that future research will lead to even more effective treatments and improve the overall outlook for children with cancer.
The progress made in pediatric cancer treatment is a testament to the dedication of researchers, clinicians, and families like Munir's. However, as Horn noted, "We just want to continue to advocate for access and improved drugs and hopefully the ability to execute the clinical trials that we need to have to qualify those drugs for patient care."
The case of six-year-old Lianna Munir, who was diagnosed with a rare form of leukemia two years ago, is a stark reminder of the progress being made in pediatric cancer treatment. Thanks to cutting-edge therapies like CAR T-cell therapy, Munir's leukemia has become undetectable, and she's now back to living a relatively normal life.
Munir's experience is just one example of how advancements in pediatric cancer treatments are revolutionizing childhood cancer care. The American Association for Cancer Research (AACR) recently released a report highlighting the successes and challenges in this field. According to the report, funding for pediatric cancer research has historically been significantly lower than that for adult cancer research.
In 2021, only about 4% of federal cancer research dollars were allocated to childhood cancer. This is concerning given the significant strides being made in developing new treatments. In the past decade, over 20 molecularly-targeted therapies and more than 10 immunotherapies have been approved for pediatric cancers, including CAR T-cell therapy.
These advancements have enabled clinicians to tailor treatment plans for specific types of pediatric cancers based on their molecular profiles. Gene editing, liquid biopsy, and artificial intelligence are also being explored as new therapeutic options.
However, despite these gains, there is still much work to be done. Pediatric brain cancers remain a leading cause of death among children, with five-year survival rates ranging from below 25% for some types. Chronic health conditions affecting children who have survived cancer are also a pressing concern, with up to 90% of survivors experiencing at least one long-term condition by adulthood.
The AACR report emphasizes the need for increased funding to continue advancing pediatric cancer research. The organization is advocating for more resources from the National Institutes of Health and other sources to develop new treatments and improve existing ones.
As Munir's mother, Adrian Horn, so eloquently put it, "If we hit a plateau, we don't have a next step to go to. We need to keep being ready for it when it doesn't work anymore." The hope is that future research will lead to even more effective treatments and improve the overall outlook for children with cancer.
The progress made in pediatric cancer treatment is a testament to the dedication of researchers, clinicians, and families like Munir's. However, as Horn noted, "We just want to continue to advocate for access and improved drugs and hopefully the ability to execute the clinical trials that we need to have to qualify those drugs for patient care."